Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 14;28(151):180063.
doi: 10.1183/16000617.0063-2018. Print 2019 Mar 31.

Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD

Affiliations
Review

Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD

Dermot Linden et al. Eur Respir Rev. .

Abstract

Chronic obstructive pulmonary disease (COPD) is currently the third most common cause of global mortality. Acute exacerbations of COPD frequently necessitate hospital admission to enable more intensive therapy, incurring significant healthcare costs. COPD exacerbations are also associated with accelerated lung function decline and increased risk of mortality. Until recently, bacterial pathogens were believed to be responsible for the majority of disease exacerbations. However, with the advent of culture-independent molecular diagnostic techniques it is now estimated that viruses are detected during half of all COPD exacerbations and are associated with poorer clinical outcomes. Human rhinovirus, respiratory syncytial virus and influenza are the most commonly detected viruses during exacerbation. The role of persistent viral infection (adenovirus) has also been postulated as a potential pathogenic mechanism in COPD. Viral pathogens may play an important role in driving COPD progression by acting as triggers for exacerbation and subsequent lung function decline whilst the role of chronic viral infection remains a plausible hypothesis that requires further evaluation. There are currently no effective antiviral strategies for patients with COPD. Herein, we focus on the current understanding of the cellular and molecular mechanisms of respiratory viral infection in COPD.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D. Linden has received grants (salary and research costs) from Mater Hospital YP Trustees. Conflict of interest: H. Guo-Parke has received grants from Pfizer. Conflict of interest: P.V. Coyle has nothing to disclose. Conflict of interest: D. Fairley reports grants to support BHSCT/QUB funding during the conduct of the study, and other support from Hibergene Diagnostics Ltd, outside the submitted work. Conflict of interest: D.F. McAuley has received a grant from the BHSCT YPC Trust, Mater Hospital for to undertake a clinical trial; personal fees (for consultancy) from GlaxoSmithKline, SOBI, Peptinnovate, Boehringer Ingelheim and Bayer; institutional grants from the UK NIHR, Wellcome Trust and other funding from GlaxoSmithKline; and is one of four named inventors on a patent US8962032 covering the use of sialic acid–bearing nanoparticles as anti-inflammatory agents issued to his institution (Queen's University of Belfast). This has no direct impact on the contents of this work. Conflict of interest: C.C. Taggart has received grants from Pfizer UK and other support for consultancy from Albumedix. Conflict of interest: J. Kidney has received grants from Pfizer UK and Mater Hospital YP Trustees. He is also the non-executive director and shareholder of Hibergene Diagnostics Ltd.

Figures

FIGURE 1
FIGURE 1
Protease/anti-protease imbalance and oxidative stress are viable pro-inflammatory mechanisms that contribute to the pathogenesis of chronic obstructive pulmonary disease (COPD). Cigarette smoke and inhaled noxious agents activate epithelial cells and macrophages to release several chemotactic factors (including interferon-γ-induced protein 10 (IP10), monokine-induced by interferon-γ (MIG), I-TAC, interleukin (IL)-6, IL-8 and leukotriene B4 (LTB4)), which attract and activate key inflammatory cells that accumulate within the airway mucosa in COPD. Sustained activation of innate and adaptive immune responses leads to airway influx of neutrophils and CD8 cytotoxic T-cells (TC1 cells)/CD4 T-helper 1 (Th1) cells. In a sub-group of COPD patients, increased Th2 signalling may be present and numerous therapies targeted at Th2 cytokines have been studied. Mepolizumab (IL-5) has shown minor reduction in acute exacerbations of COPD whilst benralizumab (IL5Ra) and navarixin (CXCR2) have shown a modest effect on forced expiratory volume in 1 s. COPD inflammatory mediators sustain the inflammatory process in COPD leading to elastin degradation and emphysema. Neutrophil elastase also causes mucus hypersecretion. Epithelial cells and macrophages also release transforming growth factor (TGF)-β, which stimulates fibroblast proliferation resulting in small airway fibrosis and remodelling. The finding of CD8+ T- and B-cells organised into follicles within the airway epithelium in COPD may represent an increased “immune surveillance” of the airway fuelling the hypothesis that an additional aetiological factor, other than exposure to inhaled noxious agents, is necessary in order to develop COPD. Chronic viral infection might serve as an additional host aetiological factor (the “missing link”) in the development of COPD, whilst increased susceptibility to acute viral-induced exacerbations leads to incremental disease progression. CTGF: connective tissue growth factor; CPE: cytopathogenic effect; TNF: tumour necrosis factor.
FIGURE 2
FIGURE 2
Mechanisms of virus-induced airway inflammation in chronic obstructive pulmonary disease (COPD). COPD exacerbations are associated with increased expression of cytokines and chemokines, including tumour necrosis factor (TNF)-α, interleukin (IL)-6, interferon (IFN)-γ-induced protein 10 (IP10), leukotriene B4 (LTB4), monokine-induced by IFN-γ (MIG), IFN-inducible T-cell-α chemoattractant and RANTES, growth regulated gene α (GRO-α) and epithelial-neutrophil activating peptide (ENA-78). These cytokines and chemokines attract various inflammatory cells such as neutrophils, T-cells, macrophages and dendritic cells. Vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF) promote the release of matrix proteins from fibroblasts/myofibroblasts, which enhance the production of matrix metalloproteinases (i.e. MMP-9) from airway epithelial cells leading to airway remodelling. Respiratory viruses preferentially target airway epithelial cells leading to epithelial cell sloughing, Goblet cell hyperplasia (mucus plug), microvascular dilatation, oedema and immune cell infiltration. Consequently, there is increased impaired mucociliary clearance and increased susceptibility to bacterial infection. Cigarette smoke contributes to impaired host innate antiviral immunity through the reduction of IFNs and IFN-stimulated gene production, and induces inflammatory mediators in the airway and increased epithelial cell apoptosis via the activation of nuclear factor (NF)-κB. In addition, dysregulated adaptive immunity may also be an important disease mechanism that may render patients with COPD more susceptible to acute viral infection. GM-CSF: granulocyte-macrophage colony stimulating factor; ICAM: intracellular adhesion molecule; TGF: transforming growth factor; I-TAC: interferon-inducible T-cell alpha chemoattractant; ISG: interferon stimulated genes; Th1: T-helper cell type 1.

References

    1. Shah T, Press VG, Huisingh-Scheetz M, et al. . COPD readmissions: addressing COPD in the era of value-based health care. Chest 2016; 150: 916–926. - PMC - PubMed
    1. Halbert RJ, Natoli JL, Gano A, et al. . Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523–532. - PubMed
    1. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5: 691–706. - PMC - PubMed
    1. Lopez AD, Shibuya K, Rao C, et al. . Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397–412. - PubMed
    1. Barnes PJ. Chronic obstructive pulmonary disease: a growing but neglected global epidemic. PLoS Med 2007; 4: e112. - PMC - PubMed

MeSH terms